In Brief: Cephalon/North American Vaccine
Executive Summary
Cephalon/North American Vaccine: $25 mil. definitive agreement for North American Vaccine to acquire Cephalon's Beltsville, Md. pharmaceutical manufacturing facility is announced Oct. 18. North American Vaccine will manufacture conjugate polysaccharide pneumococcal, group b streptococcus, and meningococcal vaccines at the Beltsville facility. Cephalon will manufacture Myotrophin in Chiron's recently completed facility in Vacaville, Calif. The company plans to file an NDA before the end of the year without an additional study...